$4.36
0.00%
Nasdaq, Tue, Oct 20 2026.
ISIN
US00773U1088
Symbol
ADVM

Adverum Biotechnologies Inc Stock price

$4.36
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
-0.10 2.24% 1Y
-5.24 54.60% 3Y
-15.74 78.31% 5Y
-29.24 87.02% 10Y
-275.54 98.44% 20Y
Nasdaq, Closing price Tue, Oct 20 2026
+0.00 0.00%
ISIN
US00773U1088
Symbol
ADVM
Industry

Is Adverum Biotechnologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$26.1m
Shares outstanding
22.0m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
39.3%
Return on Equity
-185.2%
ROCE
-327.8%
ROIC
-
Debt/Equity
0.0
Financials
Revenue | estimate
$0.0 | $12.9m
EBITDA
$-88.2m
EBIT
$-90.6m
Net Income
$-88.6m
Free Cash Flow | ex SBC
$-138.5m | $-138.2m
Growth
Revenue | estimate
-100.0% | 1,192.0%
EBITDA
24.3%
EBIT
24.7%
Net Income
20.4%
Free Cash Flow
-60.9%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-3.8
FCF per Share
$-6.3
Short interest
4.2%
Employees
155
Rev per Employee
$10.0k

Adverum Biotechnologies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

Buy
67%
Hold
33%

Financial data from Adverum Biotechnologies Inc

Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
48% 48%
-
- Research and Development Expense 63 63
8% 8%
-
-88 -88
24% 24%
-
- Depreciation and Amortization 2.49 2.49
35% 35%
-
EBIT (Operating Income) EBIT -91 -91
25% 25%
-
Net Profit -89 -89
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Adverum Biotechnologies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dr. Fischer
Employees 155
Founded 2006
Website adverum.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today